1051366-32-5
Chemical Structure
Balixafortide
Synonym(s): POL6326
- CAS No.: 1051366-32-5
- Formula:C84H118N24O21S2
- Molecular Weight:1864.11
IUPAC Name: 3-((5aR,11S,14S,17S,20R,23S,26S,29S,31aR,37S,40S,43R,46S,49S,52S,54aS)-49-((1H-imidazol-5-yl)methyl)-11-(4-aminobutyl)-29-(2-aminoethyl)-26-(3-guanidinopropyl)-17,23,52-tris(4-hydroxybenzyl)-40-(hydroxymethyl)-37,46-dimethyl-5,10,13,16,19,22,25,28,31,36,39,42,45,48,51,54-hexadecaoxodopentacontahydro-1H,5H-20,43-(methanodithiomethano)tripyrrolo[1,2-a:1',2'-b1:1'',2''-y][1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46]hexadecaazacyclooctatetracontin-14-yl)propanamide
InChIKey: MKXOUIKTXREBLX-NDKBASPVSA-N
SMILES: O=C(N(CCC1)[C@]1([H])C(N[C@H](C(N[C@H](C(N[C@H]2C)=O)CC3=CN=CN3)=O)CC(C=C4)=CC=C4O)=O)[C@](CCC5)([H])N5C([C@@H](NC([C@@H](NC([C@@H](NC([C@@](CSSC[C@](C(N[C@H](C(N[C@H](C(N6[C@]7([H])CCC6)=O)C)=O)CO)=O)([H])NC2=O)([H])NC([C@@H](NC([C@@H](NC([C@@H](NC7=O)CCN)=O)CCCNC(N)=N)=O)CC(C=C8)=CC=C8O)=O)=O)CC(C=C9)=CC=C9O)=O)CCC(N)=O)=O)CCCCN)=O
Biological Activity: Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Balixafortide | 98.20% | Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103.
- [2]. Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2. [Content Brief]
